MedTrace Logo

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

NCT00398372 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2011-06-02

No results posted yet for this study

Summary

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Conditions

  • Lymphoma, Non-Hodgkin
  • Lymphomas: Non-Hodgkin
  • Lymphomas: Non-Hodgkin Cutaneous Lymphoma
  • Lymphomas: Non-Hodgkin Diffuse Large B-Cell
  • Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
  • Lymphomas: Non-Hodgkin Mantle Cell
  • Lymphomas: Non-Hodgkin Marginal Zone
  • Lymphomas: Non-Hodgkin Peripheral T-Cell
  • Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia

Interventions

DRUG

Rituximab

DRUG

Epratuzumab

Sponsors & Collaborators

Principal Investigators

  • Wen-Kai Weng · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30
Primary Completion
2007-06-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00398372 on ClinicalTrials.gov